211 related articles for article (PubMed ID: 26556006)
41. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
42. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
44. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens.
Shields CL; Ganguly A; Bianciotto CG; Turaka K; Tavallali A; Shields JA
Ophthalmology; 2011 Feb; 118(2):396-401. PubMed ID: 20869116
[TBL] [Abstract][Full Text] [Related]
45. JARID1B protein expression and prognostic implications in uveal melanoma.
Radberger P; Radberger A; Bykov VJ; Seregard S; Economou MA
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4442-9. PubMed ID: 22669717
[TBL] [Abstract][Full Text] [Related]
46. Noncontiguous tumor recurrence of posterior uveal melanoma after transscleral local resection.
Kim JW; Damato BE; Hiscott P
Arch Ophthalmol; 2002 Dec; 120(12):1659-64. PubMed ID: 12470139
[TBL] [Abstract][Full Text] [Related]
47. Heterogeneity of monosomy 3 in fine needle aspiration biopsy of choroidal melanoma.
Chang MY; Rao NP; Burgess BL; Johnson L; McCannel TA
Mol Vis; 2013; 19():1892-900. PubMed ID: 24049435
[TBL] [Abstract][Full Text] [Related]
48. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
49. Variates of survival in metastatic uveal melanoma.
Rietschel P; Panageas KS; Hanlon C; Patel A; Abramson DH; Chapman PB
J Clin Oncol; 2005 Nov; 23(31):8076-80. PubMed ID: 16258106
[TBL] [Abstract][Full Text] [Related]
50. Anterior segment tumor biopsy using an aspiration cutter technique: clinical experience.
Petousis V; Finger PT; Milman T
Am J Ophthalmol; 2011 Nov; 152(5):771-5.e1. PubMed ID: 21794840
[TBL] [Abstract][Full Text] [Related]
51. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
52. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma.
Kim IK; Lane AM; Gragoudas ES
Arch Ophthalmol; 2010 Jul; 128(7):871-5. PubMed ID: 20625048
[TBL] [Abstract][Full Text] [Related]
53. Salvage proton beam therapy in local recurrent uveal melanoma.
Riechardt AI; Cordini D; Dobner B; Seibel I; Gundlach E; Rehak M; Hager A; Stark R; Moser L; Joussen AM
Am J Ophthalmol; 2014 Nov; 158(5):948-56. PubMed ID: 25038327
[TBL] [Abstract][Full Text] [Related]
54. Cytogenetics of uveal melanoma: a 7-year clinical experience.
Damato B; Duke C; Coupland SE; Hiscott P; Smith PA; Campbell I; Douglas A; Howard P
Ophthalmology; 2007 Oct; 114(10):1925-31. PubMed ID: 17719643
[TBL] [Abstract][Full Text] [Related]
55. Neuroendocrine tumours metastatic to the uvea: diagnosis by fine needle aspiration biopsy.
Trichopoulos N; Augsburger JJ
Graefes Arch Clin Exp Ophthalmol; 2006 Apr; 244(4):524-8. PubMed ID: 16170536
[TBL] [Abstract][Full Text] [Related]
56. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma.
Ophthalmic Oncology Task Force
Ophthalmology; 2016 Jan; 123(1):86-91. PubMed ID: 26505803
[TBL] [Abstract][Full Text] [Related]
57. RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study.
Berry D; Seider M; Stinnett S; Mruthyunjaya P; Schefler AC;
Retina; 2019 Jun; 39(6):1154-1164. PubMed ID: 29578940
[TBL] [Abstract][Full Text] [Related]
58. Fluorescent in situ hybridization for monosomy 3 via 30-gauge fine-needle aspiration biopsy of choroidal melanoma in vivo.
Young TA; Rao NP; Glasgow BJ; Moral JN; Straatsma BR
Ophthalmology; 2007 Jan; 114(1):142-6. PubMed ID: 17097737
[TBL] [Abstract][Full Text] [Related]
59. Vitreous hemorrhage after plaque radiotherapy for uveal melanoma.
Bianciotto C; Shields CL; Pirondini C; Mashayekhi A; Furuta M; Shields JA
Retina; 2012 Jun; 32(6):1156-64. PubMed ID: 22366905
[TBL] [Abstract][Full Text] [Related]
60. Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications.
Correa ZM; Augsburger JJ
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):131-5. PubMed ID: 24270974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
